{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T12:43:40Z","timestamp":1779885820558,"version":"3.53.1"},"reference-count":29,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2010,10,1]],"date-time":"2010-10-01T00:00:00Z","timestamp":1285891200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2010,10,1]],"date-time":"2010-10-01T00:00:00Z","timestamp":1285891200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"Conselleria de Sanitat de la Comunidad Valenciana, Direcci\u00f3n General de Ordenaci\u00f3n, Evaluaci\u00f3n e Investigaci\u00f3n Sanitaria","award":["AP-004\/08"],"award-info":[{"award-number":["AP-004\/08"]}]}],"content-domain":{"domain":["ajo.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Ophthalmology"],"published-print":{"date-parts":[[2010,10]]},"DOI":"10.1016\/j.ajo.2010.04.024","type":"journal-article","created":{"date-parts":[[2010,6,30]],"date-time":"2010-06-30T04:52:41Z","timestamp":1277873561000},"page":"519-528.e1","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":84,"title":["Inhibition of Corneal Neovascularization by Topical Bevacizumab (Anti-VEGF) and Sunitinib (Anti-VEGF and Anti-PDGF) in an Animal Model"],"prefix":"10.1016","volume":"150","author":[{"given":"Juan J.","family":"P\u00e9rez-Santonja","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ezequiel","family":"Campos-Mollo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariola","family":"Lled\u00f3-Riquelme","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaime","family":"Javaloy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge L.","family":"Ali\u00f3","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ajo.2010.04.024_bib1","first-page":"264","article-title":"Corneal angiogenic privilege: angiogenic and antiangiogenic factors in corneal avascularity, vasculogenesis, and wound healing (an American Ophthalmological Society thesis)","volume":"104","author":"Azar","year":"2006","journal-title":"Trans Am Ophthalmol Soc"},{"issue":"6","key":"10.1016\/j.ajo.2010.04.024_bib2","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1097\/00003226-199811000-00008","article-title":"Angiogenesis in corneal diseases: histopathologic evaluation of 254 human corneal buttons with neovascularization","volume":"17","author":"Cursiefen","year":"1998","journal-title":"Cornea"},{"issue":"6","key":"10.1016\/j.ajo.2010.04.024_bib3","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1097\/00003226-199511000-00014","article-title":"Corneal neovascularization after penetrating keratoplasty","volume":"14","author":"Dana","year":"1995","journal-title":"Cornea"},{"issue":"3","key":"10.1016\/j.ajo.2010.04.024_bib4","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1111\/j.1600-0420.2006.00659.x","article-title":"Ocular angiogenesis: the role of growth factors","volume":"84","author":"Kvanta","year":"2006","journal-title":"Acta Ophthalmol Scand"},{"issue":"5","key":"10.1016\/j.ajo.2010.04.024_bib5","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1111\/j.1600-0420.2004.00312.x","article-title":"Vascular endothelial growth factor (VEGF) and its receptor VEGFR-2 in the regulation of corneal neovascularization and wound healing","volume":"82","author":"Gan","year":"2004","journal-title":"Acta Ophthalmol Scand"},{"issue":"9","key":"10.1016\/j.ajo.2010.04.024_bib6","first-page":"2514","article-title":"Expression of vascular endothelial growth factor and its receptors in inflamed and vascularized human corneas","volume":"41","author":"Philipp","year":"2000","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"4","key":"10.1016\/j.ajo.2010.04.024_bib7","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1097\/00055735-200108000-00002","article-title":"Corneal neovascularization","volume":"12","author":"Chang","year":"2001","journal-title":"Curr Opin Ophthalmol"},{"issue":"6","key":"10.1016\/j.ajo.2010.04.024_bib8","doi-asserted-by":"crossref","first-page":"2036","DOI":"10.2353\/ajpath.2006.050588","article-title":"Inhibition of platelet-derived growth factor B signaling enhances the efficacy of anti-vascular endothelial growth factor therapy in multiple models of ocular neovascularization","volume":"168","author":"Jo","year":"2006","journal-title":"Am J Pathol"},{"issue":"2","key":"10.1016\/j.ajo.2010.04.024_bib9","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.bbrc.2007.02.156","article-title":"Sunitinib: a VEGF and PDGF receptor protein kinase and angiogenesis inhibitor","volume":"356","author":"Roskoski","year":"2007","journal-title":"Biochem Biophys Res Commun"},{"issue":"4","key":"10.1016\/j.ajo.2010.04.024_bib10","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1007\/s00417-008-0976-3","article-title":"Inhibitory effects of bevacizumab on angiogenesis and corneal neovascularization","volume":"247","author":"Han","year":"2009","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"1","key":"10.1016\/j.ajo.2010.04.024_bib11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1365-2710.2007.00800.x","article-title":"Bevacizumab, a humanized anti-angiogenic monoclonal antibody for the treatment of colorectal cancer","volume":"32","author":"Kramer","year":"2007","journal-title":"J Clin Pharm Ther"},{"issue":"3","key":"10.1016\/j.ajo.2010.04.024_bib12","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1097\/00006982-200603000-00016","article-title":"Regression of retinal and iris neovascularization after intravitreal bevacizumab (Avastin) treatment","volume":"26","author":"Avery","year":"2006","journal-title":"Retina"},{"issue":"3","key":"10.1016\/j.ajo.2010.04.024_bib13","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.ophtha.2005.11.019","article-title":"Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration","volume":"113","author":"Avery","year":"2006","journal-title":"Ophthalmology"},{"issue":"6","key":"10.1016\/j.ajo.2010.04.024_bib14","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1167\/iovs.06-0570","article-title":"Bevacizumab as a potent inhibitor of inflammatory corneal angiogenesis and lymphangiogenesis","volume":"48","author":"Bock","year":"2007","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"2","key":"10.1016\/j.ajo.2010.04.024_bib15","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1007\/s00417-007-0684-4","article-title":"Bevacizumab (Avastin) eye drops inhibit corneal neovascularization","volume":"246","author":"Bock","year":"2008","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"6","key":"10.1016\/j.ajo.2010.04.024_bib16","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1001\/archopht.125.6.834","article-title":"Topical bevacizumab therapy for corneal neovascularization","volume":"125","author":"DeStafeno","year":"2007","journal-title":"Arch Ophthalmol"},{"issue":"3","key":"10.1016\/j.ajo.2010.04.024_bib17","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1097\/ICO.0b013e31815cf67d","article-title":"Inhibition of experimental corneal neovascularization by using subconjunctival injection of bevacizumab (Avastin)","volume":"27","author":"Kim","year":"2008","journal-title":"Cornea"},{"issue":"6","key":"10.1016\/j.ajo.2010.04.024_bib18","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1136\/bjo.2006.107912","article-title":"Inhibition of experimental corneal neovascularisation by bevacizumab (Avastin)","volume":"91","author":"Manzano","year":"2007","journal-title":"Br J Ophthalmol"},{"issue":"3","key":"10.1016\/j.ajo.2010.04.024_bib19","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/j.ajo.2007.11.003","article-title":"Inhibition of corneal neovascularization by subconjunctival bevacizumab in an animal model","volume":"145","author":"Papathanassiou","year":"2008","journal-title":"Am J Ophthalmol"},{"issue":"1","key":"10.1016\/j.ajo.2010.04.024_bib20","first-page":"327","article-title":"In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic\/pharmacodynamic relationship","volume":"9","author":"Mendel","year":"2003","journal-title":"Clin Cancer Res"},{"issue":"4","key":"10.1016\/j.ajo.2010.04.024_bib21","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1089\/jop.2006.22.213","article-title":"A novel vascular endothelial growth factor receptor 2 inhibitor, SU11248, suppresses choroidal neovascularization in vivo","volume":"22","author":"Takahashi","year":"2006","journal-title":"J Ocul Pharmacol Ther"},{"issue":"2","key":"10.1016\/j.ajo.2010.04.024_bib22","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1002\/lsm.1900170207","article-title":"In vivo uptake of liposomal benzoporphyrin derivative and photothrombosis in experimental corneal neovascularization","volume":"17","author":"Schmidt-Erfurth","year":"1995","journal-title":"Lasers Surg Med"},{"issue":"4","key":"10.1016\/j.ajo.2010.04.024_bib23","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1007\/s10456-004-8272-2","article-title":"Biological activity of bevacizumab, a humanized anti-VEGF antibody in vitro","volume":"7","author":"Wang","year":"2004","journal-title":"Angiogenesis"},{"issue":"8","key":"10.1016\/j.ajo.2010.04.024_bib24","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1111\/j.1442-9071.2007.01572.x","article-title":"Bevacizumab inhibits corneal neovascularization in an alkali burn induced model of corneal angiogenesis","volume":"35","author":"Hosseini","year":"2007","journal-title":"Clin Experiment Ophthalmol"},{"issue":"3","key":"10.1016\/j.ajo.2010.04.024_bib25","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1111\/j.1600-0420.2007.01049.x","article-title":"Safety, penetration and efficacy of topically applied bevacizumab: evaluation of eyedrops in corneal neovascularization after chemical burn","volume":"86","author":"Yoeruek","year":"2008","journal-title":"Acta Ophthalmol"},{"issue":"6","key":"10.1016\/j.ajo.2010.04.024_bib26","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1111\/j.1755-3768.2008.01399.x","article-title":"Therapeutic effect of subconjunctival injection of bevacizumab in the treatment of corneal neovascularization","volume":"87","author":"You","year":"2009","journal-title":"Acta Ophthalmol"},{"issue":"10","key":"10.1016\/j.ajo.2010.04.024_bib27","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1007\/s00417-009-1099-1","article-title":"Short- and long-term safety profile and efficacy of topical bevacizumab (Avastin) eye drops against corneal neovascularization","volume":"247","author":"Koenig","year":"2009","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"5","key":"10.1016\/j.ajo.2010.04.024_bib28","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1167\/iovs.05-1071","article-title":"The role of PDGF receptor inhibitors and PI3-kinase signaling in the pathogenesis of corneal neovascularization","volume":"47","author":"Dell","year":"2006","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"7","key":"10.1016\/j.ajo.2010.04.024_bib29","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1200\/JCO.2006.06.3602","article-title":"Sunitinib: from rational design to clinical efficacy","volume":"25","author":"Chow","year":"2007","journal-title":"J Clin Oncol"}],"container-title":["American Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002939410003089?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002939410003089?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T13:00:48Z","timestamp":1757595648000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002939410003089"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,10]]},"references-count":29,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2010,10]]}},"alternative-id":["S0002939410003089"],"URL":"https:\/\/doi.org\/10.1016\/j.ajo.2010.04.024","relation":{},"ISSN":["0002-9394"],"issn-type":[{"value":"0002-9394","type":"print"}],"subject":[],"published":{"date-parts":[[2010,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Inhibition of Corneal Neovascularization by Topical Bevacizumab (Anti-VEGF) and Sunitinib (Anti-VEGF and Anti-PDGF) in an Animal Model","name":"articletitle","label":"Article Title"},{"value":"American Journal of Ophthalmology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ajo.2010.04.024","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2010 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}